<DOC>
	<DOC>NCT01341743</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of generic entecavir monotherapy or in combination with adefovir for chronic hepatitis B patients with inadequate response to NUC therapy</brief_summary>
	<brief_title>Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male or female aged 1865 years; Capable of understanding and signing the informed consent. Willing to comply with the study requirements; Serum HBsAg positive and ALT&lt;10ULN at study screening; Patients have been treated with one nucleoside/nucleotide analogue for more than 6 months and are still on treatment; History of viral breakthrough or genotypic resistance on previous therapy; History of decompensated liver function, or current signs/symptoms of decompensation e.g. ascites, variceal bleeding, encephalopathy or spontaneous peritonitis; Patient has a history of hepatocellular carcinoma(HCC) or findings suggestive of possible HCC; Other protocol defined exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>inadequate response</keyword>
	<keyword>NUC therapy</keyword>
</DOC>